Investment Thesis
- Technology platform applicable across a diverse group of proteins, carbohydrates and other molecules
- Limited risk
- New oral mechanism for proven drugs
- Proof-of-delivery is established in Phase I
- Established leading partnerships
- Six Clinical Candidates
- 8 formulations
- Lead product in Phase III
- Product candidates address a broad range of therapeutic areas
- Low cost, easy-to-scale technology